Provided is a formulation comprising: - about 10 to about 30 mg/mL of a type II anti-CD20 antibody, wherein said antibody is a humanized B-Lyl antibody, - optionally about 0.001 to about 1 % w/v of at least one pharmaceutically acceptable surfactant, and - about 1 to about 100 mM of a buffer selected from histidine-buffers, citrate-buffers, succinate-buffers, acetate-buffers and phosphate buffers, - at apH of about 4.5 to about 7.0. Further provided are variants for the formulation.
